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The menisci are a pair of semilunar fibrocartilage structures that play an essential role in maintaining normal knee
function. Injury to the menisci can disrupt joint stability and lead to debilitating results. Because natural meniscal
healing is limited, an efficient method of repair is necessary. Tissue engineering (TE) combines the principles of life
sciences and engineering to restore the unique architecture of the native meniscus. Mesenchymal stem cells (MSCs)
have been investigated for their therapeutic potential both in vitro and in vivo. This comprehensive review examines the
English literature identified through a database search using Medline, Embase, Engineering Village, and SPORTDiscus. The
search results were classified based on MSC type, animal model, and method of MSC delivery/culture. A variety of MSC
types, including bone marrow-derived, synovium-derived, adipose-derived, and meniscus-derived MSCs, has been
examined. Research results were categorized into and discussed by the different animal models used; namely
murine, leporine, porcine, caprine, bovine, ovine, canine, equine, and human models of meniscus defect/repair.
Within each animal model, studies were categorized further according to MSC delivery/culture techniques. These
techniques included direct application, fibrin glue/gel/clot, intra-articular injection, scaffold, tissue-engineered
construct, meniscus tissue, pellets/aggregates, and hydrogel. The purpose of this review is to inform the reader
about the current state and advances in meniscus TE using MSCs. Future directions of MSC-based meniscus TE
are also suggested to help guide prospective research.Introduction
The menisci are a pair of semilunar fibrocartilage struc-
tures well recognized to contribute to the maintenance
of normal knee function, facilitating joint stability, load
distribution, and joint lubrication. Importantly, partial or
total meniscectomy predisposes the joint towards osteo-
arthritis (OA) [1-3]. Meniscus repair is of special interest
to orthopedic clinicians and researchers because the
menisci are frequently susceptible to injury in a diverse
patient population [4-6].
Natural meniscal healing is limited. The outer third of
the meniscus, or the red–red zone, is well vascularized
and has a good healing capacity, while the intermediate
red–white zone and the innermost white–white zone
have poor intrinsic healing owing to their avascular* Correspondence: njomha@ualberta.ca
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unless otherwise stated.nature [7,8]. Before it was known that the menisci play
an essential role in cartilage protection and prevention
of OA, partial or total meniscectomy was widely used to
relieve the symptoms of meniscal injuries. However,
since the dire consequences of such procedures had be-
come widely recognized, more conservative approaches
have been favored [9]. Nevertheless, the removal of dam-
aged meniscus is inevitable in cases of serious meniscus
injury. In such cases, attempts can be made to replace
the damaged tissue with a functional substitute to re-
store function of normal meniscus. Although meniscus
transplantation using allografts can achieve encouraging
clinical results [10-14], concerns over many factors – tissue
availability, mismatch of size and shape of graft and host,
immunogenicity, disease transmission, and deterioration of
the allograft’s mechanical properties after implantation –
still persist [15-17]. To circumvent these problems, syn-
thetic meniscus substitutes have been tested. Specifically,
two acellular scaffolds – the collagen meniscus implant and
Actifit® (Orteq Sports Medicine, London, UK) – are in clin-
ical use. Both the collagen meniscus implant [18,19] and
Actifit® [20] have been shown to improve pain andis an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/4.0), which permits unrestricted use, distribution,
he original work is properly credited. The Creative Commons Public Domain
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one-third of collagen meniscus implant patients do not
receive any benefit and improved, well-designed, long-term
studies are needed to determine the efficacy and safety of
collagen meniscus implantation [21]. Similarly, a current
update on Actifit® notes that while preliminary published
data appear promising, there are currently no medium-
term or long-term data available for the scaffold [22].
An alternative approach to meniscus repair, especially
for less severe lesions, focuses on promoting natural
healing of the meniscus rather than replacing the dam-
aged tissue. These techniques involve conduit treatment
[23], abrasion therapy [24,25], and platelet-rich plasma
(PRP) therapy [26]. As mentioned earlier, lesions of the
inner regions of the meniscus do not heal spontaneously
owing to their lack of vascularity. Conduit treatment
supports healing of the avascular region by bridging the
area of injury to the peripheral synovial tissues [23].
Similarly, abrasion therapy promotes vascular ingrowth
to the avascular region by rasping the parameniscal
synovium and the surface of the meniscus to attract
synovial tissue and various cytokines to the injury site
[24,25]. A less invasive method of treatment involves the
use of PRP, an autologous, platelet-rich substance con-
taining various growth factors that promote healing by
enhancing meniscus cell proliferation, vascularization,
and recruitment of fibroblasts and bone marrow-derived
stem cells to the lesion [26]. Despite the benefits these
techniques may offer, the therapies have significant
drawbacks; a search for an innovative and effective treat-
ment method therefore led to the advent of a new era –
the era of meniscus tissue engineering (TE).
Cells constitute the backbone of TE. With respect
to meniscus TE, meniscal fibrochondrocytes (MFCs),
articular chondrocytes, and mesenchymal stem cells
(MSCs) have all been tested successfully for their regen-
erative potential [27]. Among the various cell sources,
MSCs are of special interest because of their multilineage
plasticity towards a variety of mesenchymal tissues [28], po-
tential immunomodulatory and anti-inflammatory proper-
ties [29,30], and extensive proliferative ability [29].
Furthermore, MSCs can migrate to the site of injury [31,32]
and exert their reparative effects not only by replacing ex-
pired or damaged tissues, but also via trophic factors [33].
The purpose of this review is to outline the advances in me-
niscus repair using MSCs, and to present the current status
and future directions of MSC-based meniscus TE. Methods
are described in Additional file 1.
Mesenchymal stem cell sources
MSCs can be isolated from various anatomical locations,
with bone marrow-derived mesenchymal stem cells
(BM-MSCs) used most commonly for meniscus TE,
followed by synovium-derived mesenchymal stem cells(SMSCs). Other sources of MSCs included adipose-derived
mesenchymal stem cells (ASCs) [34-36], meniscus-derived
mesenchymal stem cells (MeMSCs) [34,37,38], and MSCs
derived from other intra-articular and extra-articular tissues
[34,39,40] such as muscles, ligaments, periosteum, and
dermis (Table 1).
The therapeutic potential of BM-MSCs has been well
established by many in vitro and in vivo studies report-
ing that BM-MSCs promoted macroscopic and micro-
scopic healing of meniscal defects [39,41-63]. Treatment
of meniscal defects with BM-MSCs as described in these
studies resulted in abundant extracellular matrix (ECM)
production and, ultimately, in the production of meniscus-
like fibrocartilage tissue that integrated well with the
surrounding host tissue. In general, compared with their
respective controls (no BM-MSCs), the newly generated tis-
sue had improved mechanical properties [54-57]. Further-
more, BM-MSC groups showed chondroprotective effects.
Alternatively, some studies are less supportive for the
effects of BM-MSCs for meniscal healing [64-66], including
less total meniscal healing in the lesions supplemented with
exogenous fibrin clot and BM-MSCs [64]. Conversely,
those menisci that did heal using BM-MSCs showed a
more normal appearance with an increased and better ori-
ented matrix. The authors concluded that cultured autolo-
gous BM-MSCs were not beneficial for enhanced meniscal
healing despite a qualitative difference. Horse meniscal
fragments inserted into a nude mouse model were used to
investigate adhesion of two meniscal fragments with and
without the addition of BM-MSCs to allogeneic fibrin [65].
Although subjective evaluations showed improved bonding
and healing in BM-MSC-treated groups with increased vas-
cular ingrowth as compared with their controls, all other
parameters such as cell type, cell ingrowth, fibrous in-
growth, total bonding, and safranin O staining were not sig-
nificantly different. The authors stated a concern of being
underpowered with the use of eight horse menisci. Finally,
the productivity and proliferation of human BM-MSCs
were inferior to MFCs when cultured on nanofibrous scaf-
folds, although their biosynthetic outputs were similar
when cultured in pellet form [66]. This result is contrary to
the report made by the same group in an earlier study [48],
which claimed that BM-MSCs can be used as an alternative
to MFCs for meniscal TE. The absence of a preliminary
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scaffold (poly-ε-caprolactone and poly(ethylene oxide))
could have been contributors to these poor MSC results.
The therapeutic capacity of SMSCs has been demon-
strated, although studied to a less extensive degree than
that of BM-MSCs [67,82-88]. Compared with their re-
spective controls, the quantity and quality of regenerated
tissue was significantly greater in those groups treated
with SMSCs. Importantly, it has been shown that MSC
numbers in synovial fluid increased after a meniscus in-
jury in human subjects, suggesting an important role for
SMSCs in meniscus healing [86,87]. Injected SMSCs
have been shown to adhere to created meniscal defects
and differentiate into chondrocytes in vivo after injection
into a rat joint model. Unfortunately, sufficiently sized
defects were not created because healing was noted in
the control group that did not have cells injected. The
lack of difference between the SMSC-treated group and
the control group using histological analyses is therefore
not informative [89]. Meniscus regeneration by syngen-
eic, minor mismatched, and major mismatched trans-
plantation of SMSCs has been investigated in a rat
model, and it was observed that syngeneic and minor mis-
matched transplantation of SMSCs resulted in improved
meniscus healing compared with major mismatched trans-
plantation [90]. The degree of immunocompatibility be-
tween host and donor cells is thus an important factor
that can have a profound effect on the regenerative poten-
tial of stem cells. As mentioned earlier, one potential bene-
fit of MSCs is their immunosuppressive property.
However, this study advises that when using allogeneic
SMSCs, the MSC histocompatibility antigens should be
closely matched to the recipients’ antigens to achieve best
results. This could be a potential difference between
BM-MSCs and SMSCs.
Other types of MSCs, such as ASCs [35,36] and
MeMSCs [37,38], have been used successfully to pro-
mote the regeneration of meniscus in vivo. However,
there is a need to further characterize the stemness of
MeMSCs, since their isolation protocol is not different
from the widely-used native MFC isolation method, and
native MFCs have been shown to display characteristics
similar to MSCs [92]. In addition, dermis-isolated adult
stem cells produce meniscus-like tissue with robust mech-
anical properties [40]. The effectiveness of periosteum-
derived MSCs has been tested [39], but the periosteal graft
containing osteochondroprogenitor cells was deemed
ineffectual as a meniscal substitute.
The healing potential and gene expression profiles of
MSCs from different tissues have been investigated
[34,67,68]. No notable morphological differences of re-
generated meniscus between rat BM-MSC and SMSC
groups were reported, with the SMSC group performing
better than the BM-MSC group in terms of the type IIcollagen COL2 expression and electron microscopic
features [68]. Moreover, hierarchical clustering analysis
revealed that gene expression of rat meniscal cells was
closer to that of SMSCs relative to BM-MSCs. The same
researchers confirmed superior in vitro proliferation of
rabbit SMSCs compared with BM-MSCs [67]. Gene ex-
pression profiles of human MSCs derived from intra-
articular and extra-articular tissues also found that
MSCs from intra-articular tissues (such as synovium,
meniscus, and ligament) and chondrocytes were closer
to each other than those derived from extra-articular
tissues (such as muscle, extra-articular adipose tissue,
and bone marrow) [34]. There is thus the potential for
certain MSCs to be more effective in meniscal healing.
In summary, many different sources of MSCs have
been tested and shown to be effective with respect to
their therapeutic potential, but there exists a clear imbal-
ance in research efforts between different types of MSCs.
Gene expression analyses showed that intra-articular
tissue-derived MSCs such as SMSCs are genetically
closer to MFCs and MeMSCs, indicating that a more
in-depth investigation of intra-articular tissue-derived
MSCs will be beneficial. Currently, no definite answer
regarding the most optimal source of MSCs for menis-
cus repair exists and further exploration of different




The murine model has been investigated by different re-
search groups. The in vitro chondrogenic potential of rat
BM-MSCs when cultured in decellularized scaffolds
from a normal rat meniscus has been demonstrated [46].
BM-MSC seeded scaffolds showed increased expression
of ECM after 4 weeks and stiffness increased with time,
resulting in a neotissue approximating a normal menis-
cus. The same researchers used the decellularized
meniscus scaffold model and demonstrated the efficacy
of the scaffold when repopulated with rat BM-MSCs for
meniscal transplantation [51]. In addition, BM-MSCs
have been shown to proliferate in the avascular organ
culture model and contribute to meniscal healing by
producing an abundant ECM, when full-thickness circu-
lar defects of rat meniscal explants were filled with BM-
MSCs [44]. In vivo experiments using various modalities
of MSC delivery – intra-articular injection [38,47,60],
scaffolds [51], and aggregates [84] – have also success-
fully demonstrated the therapeutic potential of MSCs.
When a large number of BM-MSCs (that is, 1.0 × 107
cells) were injected into multiple-tissue-injured rat knee
joints, transplanted cells effectively mobilized to the
injured tissue and in situ MSC differentiation was ob-
served [47]. Likewise, rat or human BM-MSCs injected
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been performed resulted in promotion of rat COL2 syn-
thesis in the regenerating meniscus with chondroprotec-
tive effects [60]. Similar results were seen when human
MeMSCs were injected into rat joints whose anterior
half of the medial meniscus had been removed [38].
Even though MSCs have been shown to home to injury
sites, the effectiveness of intra-articular injection tech-
nique should be investigated further [47]. Transplant-
ation of aggregates of SMSCs regenerated meniscus
more effectively than intra-articular injection of SMSCs
[84], possibly by increasing chondrogenic potentials of
SMSCs, by applying SMSCs more directly to the menis-
cal defect, and by maintaining cell viability longer com-
pared with suspended SMSCs.
In the leporine model, MSCs administered directly
into meniscal defects or intra-articularly injected into
damaged joints resulted in promotion of fibrocartilaginous
tissue regeneration that was grossly and histologically
meniscus like [35,37,42,67,68,83] and effectively inhibited
progression of articular cartilage degeneration [37,68,83].
Various types of scaffolds, namely the type I collagen COL1
[39] and composite scaffolds [41,49,61], have been used
successfully in combination with MSCs to treat meniscal
defects: scaffolds containing MSCs produced more abun-
dant regenerative tissue that was superior in microscopic
and macroscopic quality. Caution is needed when extrapo-
lating the results to humans. Interspecies differences have
to be acknowledged [37,38,41,49,60,61,67,68,83], especially
considering the facts that animal menisci are smaller, have
different load cycles and gait pattern, and have spontaneous
healing potential (Table 2).
Large animal models
MSCs cultured in vitro via chondrogenic passaging, self-
assembly processing and micromass formation [40], as well
as in hydrogel [69] and in various types of scaffolds
[48,54,55,57], have been shown to facilitate meniscal repair
in large animals. MSCs directly applied to the injury site










Murine [38,44,46,47,51,60,65,84,89,90]as scaffold-free tissue-engineered construct [82,85] contrib-
uted to the meniscal structure and function restoration.
Application of MSCs resulted in secure defect filling with
fibrocartilaginous neotissue, showing good integration. The
repaired tissue showed a significant biomechanical im-
provement compared with controls; however, mechanical
properties were still inferior to normal tissue [52,82].
Nevertheless, MSCs prevented degeneration of meniscus
and retarded the progression of OA.
An in vivo canine model demonstrated that injection
of autologous BM-MSCs into the red–white zone tear of
lateral menisci markedly improved meniscal wound
healing compared with non-injected, control menisci
[45]. Subcutaneously implanted equine meniscal sections
with fibrin glue (MSC-free or with MSCs) into nude
mice showed no statistically significant objective results
but subjectively enhanced meniscus repair was seen in
constructs treated with MSCs/fibrin compared with
constructs treated with fibrin alone [65]. Subsequently,
the same researchers performed a prospective case series
using an in vivo equine model [62]. A total of 15 to 20
million autologous BM-MSCs were injected into the
affected joints and were followed for 2 years after the
treatment. Outcomes were evaluated using lameness
evaluation and survey. Overall, 42% of the horses
returned to or exceeded their previous work level, 33%
returned to work, although not at previous standards,
and 8% failed to return to work. These results were
compared with previous reports that treated meniscal
defects with arthroscopy alone [93,94], and intra-
articular administration of MSCs was overall a safe pro-
cedure that can bring about better clinical outcomes
than arthroscopic surgery alone for meniscal lesions
(Table 2).
Human models
For in vitro experiments, human MSCs have been cul-
tured mainly using various types of scaffolds and pellets
(Table 2). Overall, culturing on scaffolds led to the for-
mation of meniscus-like tissue that showed significantly
higher tensile strength, and axial/radial compressive
moduli comparable with those of native meniscus
[54,56]. Pellet cultures have been employed primarily for
co-culturing of MSCs with other cell types [70-73], to be
discussed later in this review.
The role of MSCs in meniscus repair has been exam-
ined in humans in vivo. As discussed earlier, the number
of MSCs in synovial fluid increased after meniscus injury
while the total MSC colony number per synovial fluid
volume was positively correlated with the postinjury
period [86,87], suggesting that MSCs play an important
role in meniscus healing. Clinically, autologous MSCs
have been intra-articularly injected into a patient suffer-
ing from meniscus injury – as documented in a case









Pellets or aggregates [40,70-73,84]
Hydrogel [69]
Others [34,40,79,86,87]
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along with 1 ml nucleated cells (isolated from fresh bone)
and 1 ml 10% v/v platelet lysate were intra-articularly
injected into a 46-year-old male patient suffering from
degenerative knee changes [50]. The patient received two
additional platelet lysate injections (supplemented with
1 ml 10 ng/ml dexamethasone) at weeks 1 and 2 post-
transplantation. Using radiographic imaging, pre-treatment
and post-treatment subjective visual analog pain scores,
and physical therapy assessments, it was concluded that the
percutaneous injection of MSCs into the ‘knee with symp-
tomatic and radiographic degenerative joint disease resulted
in significant cartilage and meniscus growth, decreased
pain, and increased joint mobility’ [50]. However, because
the patient received the platelet lysate with low-dose steroid
twice post-procedure, it is difficult to conclude that the
MSC application was the sole contributor to the physio-
logical and functional improvement. Furthermore, these
results were only 3 months post-injection.
Similarly, Pak and colleagues reported a case study in
which a percutaneous injection of autologous ASCs
along with PRP, hyaluronic acid, and CaCl2 (collectively
termed an ASC mixture) promoted the repair of a grade
II meniscal tear in a 32-year-old female [36]. The ASC
mixture was injected into the medial tibiofemoral joint
and into the medial inferior retropatellar joint on the
day of ASC collection. On the third and seventh days
after the initial injection, the patient received another
dose of PRP with CaCl2 and hyaluronic acid. On the
14th day after the initial injection, a mixture of PRP,
CaCl2, and a low-dose dexamethasone was injected. Fi-
nally, the last dose of PRP with CaCl2 was given on day
28. A comparison of the pain scores (using a functional
rating index and visual analog scale) before and 3 months
after the treatment showed significant symptom im-
provements, and a near-complete repair of the torn me-
niscus was seen on repeated magnetic resonance
imaging. Because the past treatment attempts with PRP
and hyaluronic acid injections had all failed, the authors
reasoned that the addition of ASCs led to the clinical
improvements.
A randomized, double-blind, controlled study included
55 patients who underwent a partial medial meniscec-
tomy and were randomly assigned to three different
treatments: Group A, injection of 50 million allogeneic
MSCs suspended in sodium hyaluronate/human serum
albumin/PlasmaLyte A(Baxter Healthcare Corporation)
(n = 18); Group B, injection of 150 million allogeneic MSCs
suspended in the same hyaluronate solution (n = 18); or
Group C, injection of sodium hyaluronate solution control
(n = 19) [63]. Patient assessments were performed up to
2 years postoperatively and included safety evaluation,
meniscus regeneration, overall knee joint condition, and
clinical outcomes. Sequential magnetic resonance imagingassessed the meniscus volume, cartilage degeneration, and
ectopic tissue formation. Knee pain and function were eval-
uated using a visual analog scale and the self-assessment
Lysholm knee scale. No adverse events leading to study
termination were observed. Respectively, 24% and 6% of
the patients in Groups A and B experienced a significant
meniscal volume gain (defined a priori as a 15% threshold)
as defined on magnetic resonance imaging at 1 year post-
implantation, although this decreased to 18% and 0% re-
spectively by 2 years post-implantation. No patient from
control Group C met the 15% threshold for increased
meniscal volume. Furthermore, a greater proportion of
those with OA changes experienced a reduction in pain
following the treatment with MSCs relative to the control
group. This study demonstrated that high doses of allogen-
eic MSCs can be safely injected into the knee-joint without
ectopic tissue formation and that treatment with MSCs
may lead to de novo meniscus tissue regeneration.
Current strategies and future directions
Undifferentiated versus differentiated MSCs
The choice between undifferentiated and differentiated
MSCs for meniscus repair can influence the outcome of
MSC therapy (Table 3). Insertion of a human BM-MSC-
seeded collagen scaffold between two ovine fibrocartilage
discs and subsequent histological analyses revealed that
MSCs which had been chondrogenically differentiated
using transforming growth factor beta 1 (TGF-β1) led to
significantly less integration while the undifferentiated
MSCs showed significant integration with the ovine
meniscal surface [54]. Conversely, when MSCs cultured
in chondrogenic media or in basal media were intra-
articularly injected into an ovine model (in which OA
was induced via total medial meniscectomy and resec-
tion of the anterior cruciate ligament), the chondrogenic
media group demonstrated a significant regeneration of
fibrocartilage tissue while the basal media group showed
only evidence of scarring [59]. Finally, treatment of
4 mm longitudinal meniscal tears in the avascular zone
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MSCs resulted in defect filling with repair tissue, but
also partial disintegration [61]. Meniscal lesions treated
with differentiated MSCs led to a near-complete filling
of the defects with dense repair tissue. The researchers
suggested that the necessity of treatment with undiffer-
entiated or differentiated MSCs seemed dependent on
the nature of meniscal defects.
Mechanical stimulation and perfusion
Menisci are constantly exposed to a variety of mechan-
ical stresses. Several studies have attempted to mimic
the mechanical stresses using dynamic bioreactors
[74-77]. Baker and colleagues [74] and Nerurkar and col-
leagues [75] observed that application of dynamic mech-
anical stimulation to MSC-seeded scaffolds increased the
total collagen content and promoted the maturation of
MSC-laden constructs, although they noted that dy-
namic loading can lead to marked loss in proteoglycan
content. Baker and colleagues documented a significant
improvement in mechanical properties of mechanically
stimulated constructs, while Nerurkar and colleagues
showed that dynamic culture failed to produce any sig-
nificant gain in mechanical function relative to controls.
Both groups agreed that additional work was necessary
to interpret the mechanical implications of dynamic
bioreactors, especially to reduce the gap between the
mechanical property of MSC-loaded samples and native
meniscus.
More recent studies have investigated the effect of
applying a variety of mechanical stimulation on the
structural and functional properties of TE constructs.
Petri and colleagues [77] and Liu and colleagues [76]
cultivated human BM-MSCs on scaffolds under a static
condition, with continuous perfusion (10 ml/minute), or
with both continuous perfusion (10 ml/minute) and
mechanical stimulation (10% cyclic compression at
0.5 Hz). Overall, samples under perfusion or with both
perfusion and mechanical stimulation showed enhanced
ECM accumulation and mechanical properties compared
with the static culture group. However, unlike Petri and
colleagues who found 8 hours of daily mechanical stimu-
lation with continuous perfusion beneficial, Liu and
colleagues found that 8 hours of continuous stimulation
had a negative effect. Instead, Liu and colleagues re-
ported continuous perfusion coupled with intermittent
mechanical stimulation (that is, four times daily for
2 hours each time with 4 hours of rest in between) to be
more beneficial. This discrepancy mandates further
investigation.
The combined results from these studies suggest that
perfusion and mechanical loading can enhance the quality
of TE meniscus. While the mechanical properties of TE
constructs cultivated under various perfusion/mechanicalloading conditions improved compared with constructs
under static conditions, functional properties were inferior
to those of natural meniscus. Further optimization of a
perfusion/mechanical stimulation protocol is therefore
required to produce MSC-seeded implants suitable for
clinical application.A three-dimensional niche: hydrogel and aligned
nanofibrous scaffolds
In vivo, the ECM provides scaffolding for cells. To
mimic this three-dimensional culture environment, vari-
ous biomaterials have been used to create scaffolds.
Hydrogels containing different proportions of chondro-
itin sulfate and bone marrow have been synthesized and
examined [69]. MFCs were suspended in the hydrogels
that were cultured in basal meniscus medium until har-
vest. Chondroitin sulfate–poly(ethyleneglycol) was used
as a control. Chondroitin sulfate–bone marrow hydro-
gels supported the survival, proliferation, and metabolic
activity of MFCs, unlike the chondroitin sulfate–poly
(ethyleneglycol) control. High proportions of bone mar-
row stimulated proliferation and migration of cells while
increasing the chondroitin sulfate content stimulated
ECM production and increased adhesive strength, dem-
onstrating that MSCs can be used in conjunction with
other materials and cells to enhance cell function and
matrix production for meniscus healing.
Other advancements in scaffolding technology include
the development of polyurethane scaffolds coated with a
thin layer of a novel cross-linked gelatin hydrogel system
[78], and aligned nanofibrous scaffolds [48,57,66,91].
Modified polyurethane films were developed to provide
specific cell binding sites for MSCs, allowing for ad-
equate MSC adhesion and spreading across scaffolds
[78]. Aligned nanofibrous scaffolds were engineered to
help promote maturation of MSCs and accumulation of
ECM in an organized fashion that improves mechanical
function of tissue-engineered constructs [48,57]. The
orientation and shape of cells, DNA content, total colla-
gen content, and mechanical properties of MSC-laden
scaffolds were shown to be dictated by scaffold architec-
ture: aligned nanofibrous scaffolds provided a three-
dimensional micro-pattern for guiding short-term and
long-term organization of MSCs and newly deposited
ECM, which contributed to the functional maturation of
the engineered meniscal constructs [48]. Electrospun
scaffolds of different fiber sizes – small (70 to 486 nm)
versus large (221 to 1,461 nm) – have been compared,
intending to explore how topographic cues affect matur-
ation of MSCs [91]. MSCs cultured in small fiber scaf-
folds showed a rounded/polygonal morphology, while
those cultured in large fiber scaffolds elongated in the
fiber direction. Many factors are involved in optimizing
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scaffold material, material orientation, and cell content.
Co-culture and hypoxic culture
MSCs secrete a wide range of trophic factors that can
interact with nearby cells to promote healing [33,95,96].
Although the mechanism of interaction has not been
explored, direct co-cultures of MSCs and MFCs formed
a neotissue with enhanced production of the functional
ECM of meniscus and reduced hypertrophy of MSCs
relative to pure MSCs or MFCs [70-73]. Additionally,
hypertrophic differentiation of MSCs was better sup-
pressed when MSCs were co-cultured with MFCs from
the outer meniscus relative to inner MFCs [71]. Further-
more, co-cultures of MFCs and MSCs in different pro-
portions have been examined. Comparison of bilaminar
cell pellets created using MFCs and MSCs at varying
ratios of 1:0, 3:1, 1:1, 1:3, and 0:1 determined that co-
cultures of MFCs with MSCs in a 3:1 ratio yielded the
highest levels of COL1 and glycosaminoglycan produc-
tion, as well as the lowest levels of hypertrophic genes
[70]. Saliken and colleagues [71] and Chowdhury and
colleagues [72] produced promising results using cell
pellets consisting of MFCs and BM-MSCs in a 1:3 ratio,
a ratio shown to reproducibly result in enhanced matrix
formation [73]. This discrepancy over the exact ratio of
a co-culture (that is, MFC:MSC ratio of 3:1 in Cui and
colleagues [70] and of 1:3 in Matthies and colleagues
[73]) mandates further investigation; however, the fact
that one of the benefits of a co-culture derives from re-
ducing the need for MFC expansion must be considered
in future research.
Dermis isolated adult stem cells have been used to
show that hypoxia may be an important factor for
enhancing cartilage-like properties of MSC-engineered
constructs [40,73]. The use of a co-culture system in-
stead of a monoculture system and hypoxic culture con-
ditions may help improve the quality of TE meniscus
and may mitigate the need to expand MFCs.
Genetic profiling and modification of MSCs
MSC gene expression has been investigated in an at-
tempt to better understand MSC-driven meniscus TE.
cDNA microarrays were analyzed to compare 92,160
gene expression patterns in articular and fibrocartilage
tissues with 669,160 measurements of genes expressed
in 29 other human tissues [79]. Results showed that both
hyaline and fibrocartilage tissues share very similar gene
expression patterns, and that among several mesodermal
tissues only bone marrow and nerve tissues yielded
expression patterns comparable with those of cartilage.
Eleven genes specific to both types of cartilage were
identified. These 22 genes can potentially serve as cell
markers during chondrogenesis of multipotent MSCs. Itwould be interesting to examine whether the expression
of these markers can be induced in MSCs to destine
pluripotent cells to a specific differentiation pathway.
This approach to meniscus engineering could be espe-
cially useful because the meniscus exhibits a combin-
ation of articular and fibrocartilaginous phenotypes [97].
Genetic modification of MSCs has been tested for its
efficacy. MSCs have been engineered to directly deliver
TGF-β1 [80] and human insulin-like growth factor-1 to
the site of meniscal defect [81]. Transplantation of colla-
gen–glycosaminoglycan copolymer scaffolds seeded with
TGF-β1-transduced MSCs into 5 mm longitudinal tears
in the avascular zone of the meniscus resulted in effect-
ive lesion filling with repair tissue after 3 weeks of in vi-
tro culture [80]. Stimulation with MSC-secreted TGF-β1
also increased the cellularity, deposition of proteoglycans
and COL2, and enhanced expression of meniscal genes.
The authors recognized that an uncontrolled ubiquitous
expression of TGF-β1 can lead to severe joint fibrosis
and detrimental systemic effects. Future studies should
therefore investigate methods of localized delivery of
TGF-β1 within meniscal defects. Similarly, positive as-
pects of human insulin-like growth factor-1-transfected
BM-MSCs in repairing a full-thickness model of menis-
cal defect by delivering biologically effective concentra-
tions of human insulin-like growth factor-1 have been
demonstrated [81]. Long-term studies are required to
monitor the safety and fate of these genetically modified
MSCs. Furthermore, more research is needed to explore
and determine the type and amount of growth factors
(or combination of factors) most appropriate for menis-
cus engineering.
Conclusion
Meniscus injury is common and can lead to degenerative
joint changes, given the current state of medical care,
unless significant advancements are made in meniscus
repair and regeneration technologies. TE aims to restore
the structural and functional characteristics of meniscus
by reconstructing the unique meniscus architecture.
MSCs are a useful cell source for meniscus TE. The role
and effectiveness of MSCs isolated from different ana-
tomical locations and animal models have been investi-
gated using a wide range of culture/delivery techniques.
A comprehensive review of the literature suggests that
MSCs possess an intrinsic therapeutic potential that can
directly and indirectly contribute to meniscus healing. It
is interesting that despite the positive and promising
results of MSC use in meniscus repair, few techniques
have reached clinical application. The reason for this is
unclear; however, it may reflect the complexity of the tissue
itself, partial vascularity, interspecies variability of meniscus,
multiple cell types within the tissue, and so forth. Unfortu-
nately, current research has only superficially examined
Yu et al. Stem Cell Research & Therapy  (2015) 6:86 Page 8 of 10most of these avenues and extensive work is required to
identify the best MSC source and optimize the application
of these cells. The future of meniscus TE lies in developing
ways to maximally exploit the healing capacity of MSCs.
Only with further advancements in meniscus-driven TE
can MSCs be safely and effectively applied in clinical
settings to help repair meniscus defects and to prevent or
slow the progression of OA.
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